Eugene Bauer - 13 Nov 2026 Form 4 Insider Report for Evommune, Inc. (EVMN)

SEC form
4
Accepted by SEC
17 Nov 2026, 16:37:56 UTC
Prior SEC filing
17 Apr 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Eugene Bauer filed Form 4 for Evommune, Inc. (EVMN) on 17 Nov 2026.

Key facts

  • This page summarizes Eugene Bauer's Form 4 filing for Evommune, Inc. (EVMN).
  • 4 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 17 Nov 2026, 16:37.

Change

  • Previous filing in this sequence was filed on 17 Apr 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001678620 Primary reporting owner

Bauer Eugene

Relationship
Chief Medical Officer, Director

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVMN transaction Derivative

Stock Option (Right to buy)

Disposed to Issuer

Transaction value
Shares
-100,000
Change %
-100%
Price
Shares after
0
Date
13 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
100,000
Exercise price
$18.44
Footnotes
F1, F2, F3
EVMN transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares
+100,000
Change %
Price
Shares after
100,000
Date
13 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
100,000
Exercise price
$7.63
Footnotes
F1, F2, F3
EVMN transaction Derivative

Stock Option (Right to buy)

Disposed to Issuer

Transaction value
Shares
-51,117
Change %
-100%
Price
Shares after
0
Date
13 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
51,117
Exercise price
$26.77
Footnotes
F2, F4, F5
EVMN transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares
+51,117
Change %
Price
Shares after
51,117
Date
13 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
51,117
Exercise price
$7.63
Footnotes
F2, F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 8, 2025.

Footnote F2

The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.

Footnote F3

One fourth (1/4) of the shares subject to the option award shall vest on December 8, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Footnote F4

The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.

Footnote F5

One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .